Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Stock Performance

AXDX opened at $1.39 on Tuesday. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $2.09. The company has a market capitalization of $34.81 million, a P/E ratio of -0.49 and a beta of 0.59. The stock has a fifty day moving average of $1.32 and a 200-day moving average of $1.54.

Insider Buying and Selling

In other news, Director John Patience purchased 200,000 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the purchase, the director now owns 653,224 shares of the company’s stock, valued at $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 43.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. Hedge funds and other institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.